Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Antipsychotic
56%
Adverse Drug Reaction
56%
Disease
53%
Polypharmacy
49%
Cisplatin
49%
Randomized Controlled Trial
49%
Combination Therapy
43%
Aripiprazole
39%
Chemotherapy
37%
Histone
37%
Acute Lung Injury
37%
Recurrent Disease
37%
Remission
34%
Malignant Neoplasm
32%
Symptom
30%
Immune Checkpoint Inhibitor
30%
Cohort Study
29%
Headache
28%
Typical Antipsychotic
27%
Observational Study
27%
SARS Coronavirus
26%
Clozapine
26%
Thrombocytopenia
25%
Nivolumab
24%
Lung Cancer
24%
Favipiravir
24%
Cancer Chemotherapy
24%
Vaccination Policy
24%
Treatment-Resistant Schizophrenia
24%
Colorectal Cancer
24%
Major Depression
24%
Carboplatin
24%
Olanzapine
24%
Pandemic
24%
Retrospective Study
23%
Placebo
23%
Random Effects Model
21%
Monotherapy
20%
Coronavirinae
19%
Rituximab
19%
Chronic Kidney Failure
18%
Toxic Injury
18%
Sepsis
18%
Receptor
17%
Hypnotic
16%
Acute Kidney Failure
15%
Allergic Reaction
15%
Risperidone
14%
Paliperidone
14%
Tolerability
14%
Dexamethasone
14%
Infection
14%
Diazepam
13%
Cholinergic Receptor Blocking Agent
13%
Benzodiazepine
13%
Prescription Drug
13%
Aspartate Aminotransferase
13%
Clinical Trial
13%
Fluorouracil
13%
Syndrome
13%
Depression
12%
Mouse
12%
Interstitial Lung Disease
12%
Ifosfamide
12%
Second-Line Chemotherapy
12%
Recurrence Risk
12%
Lamictal
12%
Bipolar I Disorder
12%
Drug Administration
12%
Phenylenediamine
12%
Ascorbic Acid
12%
Intraocular Hemorrhage
12%
Anemia
12%
Vertebral Canal Stenosis
12%
Asenapine
12%
Blood Toxicity
12%
Breast Cancer
12%
Hyperuricemia
12%
Nephrotoxicity
12%
CD20 Antibody
12%
Musculoskeletal Disease
12%
Thiamine
12%
Antianemic Agent
12%
High Density Lipoprotein Cholesterol
12%
Nonhodgkin Lymphoma
12%
Bendamustine
12%
Stomach Cancer
12%
Hydrocortisone
12%
Uric Acid
12%
Naldemedine
12%
Diffuse Large B Cell Lymphoma
12%
Immunoglobulin G Antibody
12%
Immunoglobulin A Nephropathy
12%
Febrile Neutropenia
12%
Antidepressant
12%
Bipolar Mania
12%
Cytomegalovirus
12%
Hemoglobin A1c
12%
Capecitabine Plus Oxaliplatin
12%
Keyphrases
Confidence Interval
29%
Major Depressive Disorder
25%
Meta-analysis
25%
Favipiravir
24%
Japanese Adverse Drug Event Report (JADER)
24%
Newer Antidepressants
24%
Systematic Meta-analysis
24%
Left DLPFC
20%
Japan
19%
Pairwise Meta-analysis
18%
Antidepressants
16%
Disease Control
15%
Risk Factors
15%
Antipsychotics
14%
Nivolumab
14%
Vortioxetine
14%
Monotherapy
14%
COVID-19
13%
Drug-induced Interstitial Lung Disease
12%
Chemotherapy
12%
Immune Checkpoint Inhibitors
12%
Second-line Chemotherapy
12%
Subjective Survey
12%
Online Team-based Learning
12%
Long-acting Injection
12%
Hair Color
12%
Lamotrigine
12%
Enrichment Design
12%
Clozapine
12%
Perm
12%
P-phenylenediamine
12%
Early Dialysis
12%
Trends Survey
12%
Intraocular Hemorrhage
12%
Renal Hypoperfusion
12%
Pressure-induced
12%
Coagulation Pathway
12%
L-OHP
12%
Steady State
12%
Nontechnical Skills for Surgeons
12%
Hyperuricemia
12%
Kaizen
12%
Bundled Interventions
12%
Drug Survey
12%
Hematopoietic Function
12%
Relapsed Lymphoma
12%
CBDCA
12%
Combination of Therapies
12%
Machine Learning Software
12%
Older People
12%
Long-acting Injectable Aripiprazole
12%
Muscle Injection
12%
5-fluorouracil (5-FU)
12%
Deltoid Injection
12%
COVID-19 Patients
12%
Sodium Zirconium Cyclosilicate
12%
HAT Therapy
12%
Pharmaceutical Consultation
12%
MRNA Vaccine
12%
Uric Acid
12%
IgA Nephropathy (IgAN)
12%
Short-acting
12%
Ocular Side Effects
12%
Febrile Neutropenia
12%
Tolerability
12%
Bipolar Mania
12%
Risk Degree
12%
Extremity Fractures
12%
Older Surgical Patients
12%
Antipsychotic Polypharmacy
12%
Post-hoc Explanation
12%
Work Outcomes
12%
Mirror-image Study
12%
Failure Mode Effect Analysis
12%
Opioid Rotation
12%
IgA Antibody
12%
Nontuberculous Mycobacterial Lung Disease
12%
Lupus Nephritis
12%
Cause-effect Analysis
12%
Fat Emulsion
12%
Elderly Female Patients
12%
Medication Pattern
12%
Fracture Risk Assessment
12%
Early Palliative Care
12%
Patients with Schizophrenia
12%
Fosaprepitant
12%
Aprepitant
12%
Neutrophil-lymphocyte Ratio
12%
Cisplatin
12%
Treatment-resistant Schizophrenia
12%
SLC47A1
12%
Gastric Cancer
12%
Secondary Pulmonary Hypertension
12%
Cancer-associated Thrombosis
12%
Nontuberculous Mycobacteriosis
12%
Treatment-resistant Depression
12%
Emetogenicity
12%
Colorectal Cancer
12%
Adjuvant Chemotherapy
12%
Liver Metastasis
12%
Medicine and Dentistry
Elderly Patient
15%
COVID-19
15%
Odds Ratio
15%
Disease
14%
Patient Safety
14%
Nivolumab
14%
Prescription Drug
13%
Outpatient
13%
Retrospective Study
13%
Spinal Stenosis
12%
Favipiravir
12%
Neutrophil
12%
Phenylenediamine
12%
Blood Toxicity
12%
Stomach Cancer
12%
Extracellular Trap
12%
End Stage Renal Disease
12%
RNA
12%
Urothelial Cancer
12%
Sodium Zirconium Cyclosilicate
12%
Symptomatic Treatment
12%
Lung Cancer
12%
Interstitial Lung Disease
12%
Computer Assisted Tomography
12%
Thrombocytopenia
12%
Cisplatin
12%
Combination Therapy
12%
Obsessive Compulsive Disorder
12%
5-HT3 Antagonist
12%
Yale-Brown Obsessive Compulsive Scale
12%
Overall Survival
12%
Operation Duration
12%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Clinical Trial
12%
Limb Fracture
12%
Naldemedine
12%
Second-Line Chemotherapy
12%
Histone
12%
Acute Lung Injury
12%
Polypharmacy
12%
Surgeon
12%
Lupus Nephritis
12%
Lipid Emulsion
12%
Immunoglobulin A Antibody
12%
Febuxostat
12%
Diabetic Nephropathy
12%
Anaphylaxis
12%
Senescence
12%
Physical Performance
12%
Surgery
12%
Logistic Regression Analysis
12%
Open Lung Biopsy
12%
Pemetrexed
12%
Patient with Psychiatric Disorder
12%
CD11b Antigen
12%
Immune Checkpoint Inhibitor
12%
Contrast Medium
12%
Cancer Chemotherapy
12%
Gemcitabine
12%
Mycobacteriosis
12%
Capecitabine Plus Oxaliplatin
12%
Antidepressant
12%
Tipiracil Plus Trifluridine
12%
Dorsolateral Prefrontal Cortex
12%
Pharmacovigilance
12%
Liver Metastasis
12%
Adjuvant Chemotherapy
12%
Recurrent Disease
12%
Surgery
12%
Colorectal Carcinoma
12%
Nutrition
12%
Chemotherapy-Induced Nausea and Vomiting
10%
Diagnosis
9%
Catheter Infection
8%
Multivariate Analysis
8%
Endothelial Cell Antibody
8%
Platelet
8%
Placebo
8%
mRNA Vaccine
7%
Injection
7%
Esomeprazole
7%
Quality Improvement
6%
Psychiatric Treatment
6%
Progressive Disease
5%
Patient Referral
5%